Roche and Eli Lilly's Blood Test for Alzheimer's Disease Receives FDA Approval

Gelonghui October 13 | Roche Diagnostics announced that the U.S. Food and Drug Administration (FDA) has approved its blood test product, developed in partnership with Eli Lilly and Company, as an auxiliary tool for the preliminary assessment of Alzheimer's disease. This approval follows the FDA's May authorization of Fujirebio Diagnostics' Lumipulse blood test, which was the first device of its kind approved for diagnosing this neurodegenerative condition.